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The β3-adrenergic receptor agonist mirabegron
improves glucose homeostasis in obese humans
Brian S. Finlin,1,2 Hasiyet Memetimin,1,2 Beibei Zhu,1,2 Amy L. Confides,3,4 Hemendra J. Vekaria,5 Riham H. El Khouli,6
Zachary R. Johnson,1,2 Philip M. Westgate,7 Jianzhong Chen,8,9 Andrew J. Morris,8,9 Patrick G. Sullivan,5
Esther E. Dupont-Versteegden,3,4 and Philip A. Kern1,2
Division of Endocrinology, Department of Internal Medicine, and 2Barnstable Brown Diabetes and Obesity Center, College of Medicine, 3Department of Physical Therapy, College of Health Sciences, 4Center

1

for Muscle Biology, 5Spinal Cord and Brain Injury Research Center, and 6Department of Radiology, College of Medicine, 7College of Public Health, and 8Division of Cardiovascular Medicine, Department of
Internal Medicine, College of Medicine, University of Kentucky, Lexington, Kentucky, USA. 9Lexington Veterans Affairs Medical Center, Lexington, Kentucky, USA.

BACKGROUND. Beige adipose tissue is associated with improved glucose homeostasis in mice. Adipose tissue contains β3adrenergic receptors (β3-ARs), and this study was intended to determine whether the treatment of obese, insulin-resistant
humans with the β3-AR agonist mirabegron, which stimulates beige adipose formation in subcutaneous white adipose tissue
(SC WAT), would induce other beneficial changes in fat and muscle and improve metabolic homeostasis.
METHODS. Before and after β3-AR agonist treatment, oral glucose tolerance tests and euglycemic clamps were performed,
and histochemical analysis and gene expression profiling were performed on fat and muscle biopsies. PET-CT scans quantified
brown adipose tissue volume and activity, and we conducted in vitro studies with primary cultures of differentiated human
adipocytes and muscle.
RESULTS. The clinical effects of mirabegron treatment included improved oral glucose tolerance (P < 0.01), reduced hemoglobin
A1c levels (P = 0.01), and improved insulin sensitivity (P = 0.03) and β cell function (P = 0.01). In SC WAT, mirabegron treatment
stimulated lipolysis, reduced fibrotic gene expression, and increased alternatively activated macrophages. Subjects with the
most SC WAT beiging showed the greatest improvement in β cell function. In skeletal muscle, mirabegron reduced triglycerides,
increased the expression of PPARγ coactivator 1 α (PGC1A) (P < 0.05), and increased type I fibers (P < 0.01). Conditioned media
from adipocytes treated with mirabegron stimulated muscle fiber PGC1A expression in vitro (P < 0.001).
CONCLUSION. Mirabegron treatment substantially improved multiple measures of glucose homeostasis in obese, insulinresistant humans. Since β cells and skeletal muscle do not express β3-ARs, these data suggest that the beiging of SC WAT by
mirabegron reduces adipose tissue dysfunction, which enhances muscle oxidative capacity and improves β cell function.
TRIAL REGISTRATION. Clinicaltrials.gov NCT02919176.
FUNDING. NIH: DK112282, P30GM127211, DK 71349, and Clinical and Translational science Awards (CTSA) grant UL1TR001998.

Introduction

The β3-adrenergic receptor (β3-AR) has long been a therapeutic
target to combat obesity and metabolic disease. Since the β3-AR
is present in adipose tissue, but not in most other tissues, an
agonist would activate thermogenesis in adipose tissue, stimulating lipid oxidation and glucose consumption to produce heat
(1, 2) without causing cardiovascular side effects. Much initial
work has been performed in rodents, which maintain brown
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adipose tissue (BAT) throughout adulthood to defend against
cold; indeed, treatment of rodents with β3-AR agonists activates BAT, resulting in increased energy expenditure, weight
loss, and improved glucose and lipid metabolism (3–5). In addition to stimulating white adipose tissue (WAT) lipolysis, it is
now recognized that β3-AR activation (or cold exposure) induces the formation of brown adipocytes in subcutaneous WAT (SC
WAT) (6), which are now called beige adipocytes (7). Recent
studies using tissue transplantation or genetic approaches
have demonstrated that beige adipose tissue is associated with
improved glucose and lipid homeostasis (8–12).
BAT is highly specialized and functions to generate heat in
response to activation of the sympathetic nervous system through
nonshivering thermogenesis (13). The adipocytes in BAT have
higher levels of mitochondria than do those in WAT, and these
mitochondria have high levels of uncoupling protein 1 (UCP1).
Activation of the sympathetic nervous system stimulates lipolyjci.org   Volume 130   Number 5   May 2020
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Figure 1. Flow chart of the study design and analysis of the research participants. Sixty-seven research subjects were assessed, and 39 were randomized
into 3 drug treatment groups. The results for the subjects in the pioglitazone and combination therapy groups will be presented in a future publication.
Thirteen subjects were in the mirabegron treatment group, and all completed the study.

sis and UCP1 activation in BAT, causing energy to be converted
to heat and consuming lipids and glucose (13). BAT is present in
adult humans (14–17) and is associated with improved insulin
sensitivity and glucose homeostasis (recently reviewed in ref.
18). However, BAT diminishes with age and obesity, and there are
questions about whether BAT activation is feasible therapeutically
in the older, insulin-resistant human population that would be the
logical target for drug treatment (19).
Beige adipocytes are unique, since they have a different developmental origin than brown adipocytes and are highly inducible
by cold exposure or β-AR agonism (recently reviewed in ref. 20).
Recent studies in mice have demonstrated that beige adipocytes
can activate glycolytic pathways and improve glucose metabolism independently of UCP1 (21) and that futile metabolic cycles
act in addition to UCP1-mediated uncoupled respiration (21, 22).
Beiging is also associated with reduced adipose tissue fibrosis and
adipose dysfunction (11, 23). These findings suggest that inducing beige adipose tissue may improve metabolic homeostasis by
2320
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increasing the ability of SC WAT to function as a metabolic sink
for glucose and lipids (20) or by reducing the WAT dysfunction
that occurs with obesity (24, 25). Substantial beiging of human
SC WAT has been demonstrated with cancer cachexia, burns, and
conditions with high catecholamine levels (26–29), and we have
demonstrated the induction of UCP1 and beige adipose markers
in SC WAT in response to cold (30). However, to our knowledge,
no study in humans has demonstrated a link between beige fat and
glucose or lipid metabolism.
Mirabegron is a β3-AR agonist that is FDA approved for the
treatment of overactive bladder at a maximal dose of 50 mg /
day. In recent human studies, acute mirabegron treatment
increased BAT activity and resting energy expenditure in lean
humans with demonstrable baseline levels of BAT in a dose-dependent manner (31–33). We treated a cohort of human subjects
who were older, obese, and insulin resistant with mirabegron for
12 weeks and observed that chronic mirabegron treatment stimulated SC WAT beiging (30).
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Table 1. Baseline characteristics of study subjects
and treatment responses
MirabegronA
Number (Sex, male/female)
Age (yr)
BMI (kg/m2)
Weight (kg)
Systolic BP (mmHg)
Diastolic BP (mmHg)
Heart rate (beats/min)
Fasting glucose (mg/dL)
Fasting insulin (μU/mL)
120-minute glucose (mg/dL)
HbA1c (%)
TG (mg/dL)
Cholesterol (mg/dL)
HDL (mg/dL)
LDL (mg/dL)

P valueB

Before

After

13 (2/11)
54.8 ± 2.2
32.4 ± 1.1
88.0 ± 2.6
127.8 ± 4.8
79.8 ± 2.3
68.7 ± 1.6
97.0 ± 2.8
13.2 ± 2.7
135.3 ± 7.5
5.6 ± 0.1
144.0 ± 22.9
215.7 ± 11.2
56.6 ± 5.1
132.9 ± 7.8

87.5 ± 2.6
125.5 ± 3.5
81.4 ± 2.6
70.7 ± 1.8
95.8 ± 3.1
14.4 ± 2.3
109.8 ± 6.4
5.4 ± 0.1
130.1 ± 18.0
205.7 ± 11.6
55.9 ± 4.7
125.4 ± 8.6

0.34
0.42
0.61
0.32
0.49
0.4
< 0.01
0.01
0.35
0.09
0.71
0.15

Research participants were treated with mirabegron (50 mg/day) for 12
weeks. Data indicate the mean ± SEM (n = 13). BData were analyzed by a
paired, 2-tailed Student’s t test.
A

Here, we present the results of extensive metabolic phenotyping of an expanded cohort of obese, insulin-resistant subjects before
and after mirabegron treatment. We found that mirabegron treatment substantially improved glucose homeostasis and addressed
many of the underlying mechanisms of insulin resistance, including improved insulin sensitivity and secretion and improved adipose tissue and skeletal muscle lipotoxicity and inflammation, yet
had no effect on BAT in these older, obese individuals.

Results

Effect of mirabegron treatment on lipid and glucose homeostasis. A flow
diagram showing the subject recruitment and study design is shown
in Figure 1. We observed no significant change in body weight after
treatment with mirabegron (Table 1). Consistent with this, mirabegron treatment did not change any measure of body composition
(Supplemental Table 1; supplemental material available online
with this article; https://doi.org/10.1172/JCI134892DS1) or resting
energy expenditure (Supplemental Table 2). Mirabegron treatment
did not significantly change plasma lipid levels, although there was
a trend toward a reduction in total cholesterol (Table 1; P = 0.09). In
addition, there were no reported side effects, in particular, no cardiovascular side effects such as palpitations or rapid pulse. Blood
pressure and heart rate did not change with treatment (Table 1),
consistent with previous studies (34).
We assessed glucose homeostasis with an oral glucose tolerance test (OGTT) and measurement of hemoglobin A1c (HbA1c)
levels. Fasting blood glucose was not affected by mirabegron
treatment (Table 1); however, mirabegron treatment significantly
improved overall oral glucose tolerance (P < 0.01; n = 12), as shown
in Figure 2A. The glucose concentration 120 minutes after oral
glucose ingestion was significantly lower after mirabegron treatment (Table 1; P < 0.01). A subset of subjects had impaired glucose

tolerance, and their 120-minutes glucose levels decreased from
165 mg/dL to 120 mg/dL after treatment. Among the 13 subjects,
9 had prediabetes according to American Diabetes Association
criteria (i.e., having any one of the following: fasting glucose levels
of 100–125 mg/dL, 120-minute glucose levels of 140–199 mg/dL,
or HbA1c between 5.7% and 6.4%). Following mirabegron treatment for 12 weeks, 5 of the 9 subjects were no longer prediabetic
(i.e., did not meet any of the criteria described above). Overall,
these subjects did not have diabetes, and the mean HbA1c level
of the group was 5.6% ± 0.1% at baseline (Table 1). HbA1c was
significantly lower after mirabegron treatment (Table 1; P = 0.01),
consistent with the overall improvement in glucose tolerance.
Insulin sensitivity and pancreatic β cell function. To determine
the underlying mechanisms for the improved glucose tolerance,
we evaluated insulin sensitivity and pancreatic β cell function
using the results obtained from both the OGTT and euglycemic
clamp. Mirabegron treatment did not significantly change baseline insulin levels (Table 1), nor did it change the homeostatic
model assessment of insulin resistance (HOMA-IR) or the Matsuda index, which are measures of insulin sensitivity derived
from the results of the OGTT (33). However, the results from
euglycemic clamps, which are the gold standard for measuring
insulin sensitivity (35), revealed that mirabegron treatment consistently and significantly increased the glucose infusion rate
(GIR) by approximately 12% (Figure 2B; P = 0.03). Using glucose and insulin values from the OGTT, we calculated the insulinogenic index as an indicator of unadjusted insulin secretion.
Using the insulin sensitivity from the clamp and the insulinogenic
index, we then calculated insulin secretion adjusted for insulin
sensitivity to obtain the disposition index value (36). We found
that mirabegron treatment significantly increased both the insulinogenic index (Figure 2C; P = 0.02) and the disposition index
(Figure 2D; P = 0.01), indicating improved β cell function. We
measured insulin levels during the OGTT (Supplemental Figure
1A) and the euglycemic clamps (Supplemental Figure 1B) and
did not find evidence that mirabegron changed insulin clearance
rates. Finally, although there was no significant weight loss, some
individuals did weigh less after mirabegron treatment. We therefore performed analyses to determine whether the percentage of
weight change influenced insulin sensitivity, but found no significant relationship (P = 0.55). Together, these results indicate
that the improvement in glucose tolerance was the result of both
increased β cell function and improved insulin sensitivity.
Beige adipose tissue and BAT. The β3-AR has a restricted tissue
distribution, with expression reported in white and brown adipocytes and bladder smooth muscle cells. It is thus possible that the
effects on insulin sensitivity and β cell function observed in our
study were not direct but rather the result of SC WAT beiging or
brown fat induction. Indeed, the activity of both beige adipose tissue and BAT is associated with improved glucose homeostasis and
postulated to involve the secretion of “batokines” to communicate
with peripheral tissues (20). In previous studies, mirabegron was
demonstrated to cause an acute increase in BAT activity in young,
lean male subjects with detectable levels of BAT at baseline and
was more effective at the higher dose of 200 mg, which is 4 times
the FDA-approved dose (31, 32). To determine whether chronic mirabegron treatment (50 mg/day) increased BAT activity in
jci.org   Volume 130   Number 5   May 2020
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Figure 2. Mirabegron treatment improves glucose homeostasis in obese, insulin-resistant subjects. Subjects were treated with mirabegron (50 mg/
day) for 12 weeks. OGTTs and euglycemic clamps were performed at baseline and after treatment. (A) OGTT results and AUC for all subjects (n = 12). Data
indicate the mean ± SEM. OGTT data were analyzed by a 2-way, repeated-measures ANOVA (***P < 0.001 and ****P < 0.0001); AUC data were analyzed
by a paired, 2-tailed Student’s t test (**P < 0.01). (B) Euglycemic clamping was performed at an insulin infusion rate of 1.0 mU/kg/min, and the GIR was
determined before and after treatment. Data indicate the mean ± SEM (n = 13) and were analyzed by a paired, 2-tailed Student’s t test (*P < 0.05). (C)
The insulinogenic index was determined from the results of the oral glucose tolerance test. Data indicate the mean ± SEM (n = 12) and were analyzed by a
paired, 2-tailed Student’s t test (*P < 0.05). (D) The disposition index is the product of (C) insulin sensitivity and (D) the insulinogenic index. Data indicate
the mean ± SEM (n = 12). **P < 0.01, by paired, 2-tailed Student’s t test. (E) BAT volume was quantified by PET-CT scans before and after treatment. Eight
subjects had no BAT at baseline, and BAT did not increase after treatment of these subjects. (F) The change in SC WAT beiging was calculated as the
difference in UCP1 protein expression before and after treatment. The change in the disposition index (D) and the change in UCP1 in SC WAT were analyzed
by regression analysis. The Spearman’s correlation coefficient and P value are indicated in F.

older, insulin-resistant individuals, we performed cold-stimulated PET-CT before and after mirabegron treatment. As shown
in Figure 2E, mirabegron treatment did not increase BAT volume.
Notably, 8 of the subjects had no demonstrable BAT at baseline,
and there was no increase in BAT in these subjects following mirabegron treatment. There was also no increase in any measure of
glucose uptake by BAT (Supplemental Table 3).
We previously observed that mirabegron treatment significantly induced beiging of SC WAT in 6 subjects (30) who were
among the 13 subjects in this report. Consistent with that study, we
found that mirabegron treatment increased protein expression of
the beige adipose markers UCP1 (2.4-fold, P < 0.0001), transmembrane protein 26 (TMEM26) (4.2-fold, P < 0.001), and cell death–
inducing DFFA-like effector A (CIDEA) (2.4-fold, P < 0.01) in SC
WAT within the entire cohort (n = 13). Since mirabegron treatment
increased beige fat, we determined whether the change in adipose
beiging correlated with the changes in insulin sensitivity or the disposition index. This analysis revealed that the change in UCP1 protein expression in SC WAT significantly correlated with the change
in the disposition index, indicating a possible beneficial relationship between beige fat and pancreatic β cell function (Figure 2F; P
= 0.05). Although we found a relationship between the change in
UCP1 protein expression in SC WAT and the insulinogenic index,
this change did not reach statistical significance (r = 0.46; P = 0.12).
The change in UCP1 protein expression in SC WAT did not significantly correlate with the change in the GIR (P = 0.27).
2322
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Systemic inflammation and skeletal muscle lipotoxicity. Inflammation and lipotoxicity are both implicated in the development
of insulin resistance and reduced β cell function in the context of
obesity in humans. We measured plasma levels of adiponectin,
high-molecular-weight (HMW) adiponectin, TNF-α, and monocyte chemoattractant protein 1 (MCP1). Plasma levels of TNF-α,
MCP1, or total or HMW adiponectin did not change after mirabegron treatment (Supplemental Table 4). We measured triglyceride
(TG), diacylglyceride (DAG), and ceramide levels in vastus lateralis muscle biopsies to determine whether mirabegron treatment
reduced lipotoxicity. Mirabegron treatment caused a slight reduction in TG levels (Figure 3A; P = 0.04) but did not reduce levels of
the lipotoxic lipids ceramide or DAG (Figure 3, B and C).
We investigated mechanisms for the reduction in muscle TG.
PPARγ coactivator 1 α (PGC1α) is part of a transcriptional network
that regulates muscle fiber type determination and promotes fatty
acid oxidation, mitochondrial biogenesis, and type I fiber formation (37, 38). PGC1A mRNA expression was significantly increased
in muscle following mirabegron treatment (Figure 3D; P < 0.05).
Both mitochondrial transcription factor A (TFAM1) and cyclooxygenase IV (COX IV) were increased after mirabegron treatment
(Figure 3, E and F; P < 0.01), consistent with the induction of
PGC1A. In addition to PGC1A, we measured the mRNA expression of perilipin 5 (PLIN5), which is associated with increased
insulin sensitivity. This increase is thought to be due to the ability
of PLIN5 to promote fatty acid oxidation (39). We observed that

The Journal of Clinical Investigation  
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Figure 3. Mirabegron treatment reduces skeletal muscle TGs, but not toxic lipids, and promotes fiber-type switching to type I fibers. Lipids were
extracted from skeletal muscle obtained from vastus lateralis biopsies and the levels of the indicated lipids were measured as described in Methods.
The levels of (A) TG, (B) DAG, and (C) ceramide before and after mirabegron treatment were determined. (D–G) mRNA expression of genes in muscle was
determined by real-time RT-PCR. (H) Representative images of muscle stained for MyHC I, MyHC IIa, and MyHC IIx before and after mirabegron treatment.
Scale bars: 50 μm. (I–L) Quantification of type I, type IIa, and type IIx fibers. Data are expressed as the percentage of total fibers and indicate the mean ±
SEM (n = 12–13). *P < 0.05 and **P < 0.01, by paired, 2-tailed Student’s t test.

PLIN5 was upregulated with mirabegron treatment (Figure 3G; P <
0.01). A possible explanation for these changes in gene expression
is that mirabegron treatment changed the fiber type composition
of skeletal muscle; therefore, we quantified type I, type IIa, type
IIx, and type IIa /IIx fibers. As shown in Figure 3, H–L, the percentage of type I fibers significantly increased (P < 0.01), the percentage of type IIa fibers significantly decreased (P < 0.05), and
neither type IIx nor type IIa/IIx fibers changed following mirabegron treatment.
Real-time reverse transcription PCR (RT-PCR) revealed no
mRNA expression of the β3-AR in muscle; as expected, we were
able to detect mRNA expression of the β2-AR (data not shown).
Activation of the β2-AR causes skeletal muscle hypertrophy (40);
however, we did not detect an increase in the size of the muscle
fibers (data not shown), suggesting that mirabegron did not cause
activation of β2-ARs at the dose used in this study. Thus, these

changes in skeletal muscle induced by mirabegron treatment are
probably caused by an indirect mechanism that is possibly related to SC WAT beiging. To test this concept in vitro, we prepared
conditioned medium (CM) from untreated adipocytes and from
adipocytes treated with mirabegron for 16 hours. We then treated
differentiated human myotubes with mirabegron, CM from differentiated human adipocytes, or CM from adipocytes treated with
mirabegron for 16 hours. We found that CM from untreated adipocytes did not induce PGC1A mRNA expression in myotubes; however, myotubes that were incubated with CM from adipocytes that
were treated with mirabegron had significantly increased levels of
PGC1A expression (Figure 4; P < 0.001), suggesting that mirabegron treatment caused adipocytes to release a factor that induced
PGC1A mRNA expression in muscle. As an additional control to
account for any effect of mirabegron on myotubes, we harvested
CM from adipocytes and then added mirabegron to it and treatjci.org   Volume 130   Number 5   May 2020
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Figure 4. CM isolated from adipocytes treated with mirabegron induces
PGC1α expression in human myotubes in vitro. Differentiated human
adipocytes, with or without 100 nM mirabegron treatment for 16 hours,
and the CM was isolated as described in Methods. An additional control
was made by adding mirabegron to the CM after the CM was isolated from
the adipocytes. The human myotubes were then incubated with 0.025%
DMSO (Control), mirabegron (25 nM), adipocyte CM (25%), mirabegron-treated adipocyte CM (25%), or adipocyte CM plus mirabegron (25%).
The final concentration of mirabegron was 25 nM. Data indicate the mean
± SEM (n = 3). *P < 0.05 and ***P < 0.001, by 1-way ANOVA with Tukey’s
multiple comparisons test.

ed myotubes with this medium. CM from adipocytes treated with
mirabegron induced higher PGC1A expression in myotubes than
did media in which mirabegron was added after harvesting the
CM from adipocytes. (Figure 4; P < 0.05).
Adipose tissue remodeling. We have previously reported that
phospho–hormone–sensitive lipase (HSL) is increased after mirabegron treatment (30), suggesting that mirabegron stimulates
cAMP signaling in adipocytes. To determine whether mirabegron
treatment stimulates lipolysis, we measured nonesterified fatty
acids (NEFAs) and glycerol in the CM from adipose explants from
subjects before and after treatment. We found that glycerol was significantly higher in the medium of adipose tissue after mirabegron
treatment (Figure 5A; P < 0.01) and that plasma NEFA levels were
higher after mirabegron treatment (Figure 5B; P < 0.05). Elevated
plasma NEFA levels are thought to contribute to ectopic lipid accumulation and inhibition of insulin receptor signaling in the liver and
skeletal muscle. Acute exposure of β cells to NEFAs stimulates insulin secretion, but chronic exposure causes lipotoxicity and inhibits
insulin secretion (41–43). As described above, ceramide and DAG
levels in skeletal muscle were not elevated, despite the increase in
plasma NEFAs. This raises the interesting possibility that β3-AR
stimulation of beiging induces compensatory mechanisms, such as
the fiber-type switching to the more oxidative type I muscle fibers
described above, allowing for improved peripheral tissue function
even in the presence of increased plasma NEFA levels.
To gain further insight into the effects of mirabegron on adipose tissue, we analyzed SC WAT gene expression before and after
treatment using the NanoString nCounter Multiplex system. The
panel of 160 genes consisted of adipokines, cytokines, immune
cell markers, and genes involved in adipocyte function, angiogenesis, and fibrosis (Supplemental Table 5). Fatty acid–binding protein
4 (FABP4) mRNA expression was significantly induced following
mirabegron treatment (Table 2; P < 0.01). FABP4, a lipid chaperone,
is regulated by fatty acids (44) and is probably induced by mirabegron treatment in response to increased lipolysis. Collagen 6 and
elastin as well as metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) were significantly changed by mirabegron
2324
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treatment, and most of these were lower after treatment (Table 2),
suggesting a reduction in extracellular matrix (ECM) remodeling.
The mRNA expression levels of 2 genes encoding secreted proteins
with known effects on insulin resistance were changed: fibroblast
growth factor 21 (FGF21), which has overall beneficial effects on
metabolic homeostasis, was induced by mirabegron treatment, and
resistin, which is associated with insulin resistance, was suppressed
by mirabegron treatment. Retinol-binding protein 4 (RBP4) mRNA
expression was elevated; RBP4 is a secreted protein that is postulated to promote local adipose tissue inflammation; however, we did
not find increased inflammatory gene expression. Also, mirabegron
treatment did not affect the expression of any of the β-ARs (Supplemental Figure 2). Overall, mirabegron treatment yielded many
changes in SC WAT gene expression that indicated a shift toward
an improvement in adipose tissue function. Finally, we found that
mirabegron did not induce changes in the plasma levels of resistin,
FGF21, adipsin, or leptin proteins (Supplemental Table 4).
To assess adipose tissue inflammation, we measured adipose
tissue macrophage polarization in response to mirabegron. The
numbers of CD163+CD68+ macrophages were increased in SC

Table 2. Changes in SC WAT gene expression caused by mirabegron
Gene symbolA

Function

Fold change

P valueB

FABP4
RBP4
TIMP2
COL6A1
Angiopoietin 3
DGAT2
Angiopoietin 4
MMP2
PPARG2
Resistin
FGF21
CERS6
PKCA
Elastin
GM-CSF
MMP14

Fatty acid metabolism
Secreted factor
ECM
ECM
Angiogenesis
Lipid metabolism
Angiogenesis
ECM
Transcription factor
Secreted factor
Secreted factor
Lipid metabolism
Kinase
ECM
Cytokine
ECM

1.22
1.24
0.85
0.89
0.81
1.24
1.19
0.69
1.18
0.67
1.21
1.11
0.87
0.76
0.83
0.88

< 0.01
< 0.01
< 0.01
0.02
0.03
0.03
0.03
0.03
0.04
0.04
0.04
0.04
0.05
0.05
0.05
0.05

Research participants were treated with mirabegron (50 mg/day) for
12 weeks, and gene expression was measured at baseline and after
treatment. Data represent mean ± SEM (n = 13). BData were analyzed by
a paired, 2-tailed Student’s t test. Additional information is available in
Supplemental Table 5.

A
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Figure 5. Mirabegron treatment stimulates lipolysis. (A) Adipose tissue
(0.5 g) from the SC WAT biopsy was placed in medium and kept at 37°C for 1
hour, and the level of glycerol was determined in the adipose tissue explant
CM before and after treatment. (B) Plasma NEFA levels were determined
before and after treatment. Data indicate the mean ± SEM (n = 13). **P <
0.01 and ***P < 0.001, by paired, 2-tailed Student’s t test.

WAT after mirabegron treatment (P < 0.05), but the numbers of
CD86+CD68+ macrophages were not changed (Figure 6, A and
B). This result indicates a shift toward M2 macrophage polarization and suggests reduced adipose dysfunction, consistent with
the results of the gene expression analysis. Finally, we found
that UCP1 was often present as punctate staining in small cells
between the large, unilocular adipocytes. UCP1 staining colocalized with CD163, and UCP1+CD163+ cells significantly increased
in SC WAT after mirabegron treatment (Figure 6, C and D; P
< 0.001). These results suggest that UCP1 is not only present in
beige adipocytes but is also expressed in alternatively activated
macrophages, which may play an important role in beige adipose
tissue in humans.
SC WAT mitochondrial bioenergetics. We previously demonstrated that repeated cold exposure increases mitochondrial
uncoupling in SC WAT (30). Using similar methods, we examined
the bioenergetic profiles of purified mitochondria from SC WAT
before and after mirabegron treatment by measuring state 3 and
state 4 respiration, uncoupling activity, and maximal respiration.
The bioenergetic profiles before and after treatment with mirabegron are shown in Figure 7, A and B. To measure UCP1-driven
uncoupling, we calculated the difference between the oxygen
consumption rates (OCRs) obtained during the presence of oligomycin and then free fatty acids (FFAs), which were subsequently added to stimulate uncoupling. Although mirabegron induced
UCP1 protein expression, it did not increase uncoupled respiration. However, respiration in the presence of oligomycin (state 4)
was lower after mirabegron treatment (Figure 7, A and B). As part
of our experimental protocol, we added BSA after the addition
of FFAs to sequester the FFAs, which demonstrated the effects

of FFAs on uncoupling. The OCR after BSA addition was lower
than the OCR after oligomycin addition, both before (Figure 7A)
and after treatment (Figure 7B), and this difference (Oligo – BSA)
likely reflects stimulation of uncoupled respiration by endogenous
FFAs or ROS, both of which are sequestered by BSA. As shown in
Figure 7C, Oligo – BSA was significantly lower after mirabegron
treatment (P < 0.05). The reduction in uncoupled respiration
(Oligo – BSA) and the increase in metabolic efficiency likely reflect
a beneficial effect of mirabegron treatment on SC WAT.
Summary and conclusions. Mirabegron treatment improved
glucose homeostasis in obese, insulin-resistant subjects. The
underlying mechanisms involve both increased insulin sensitivity
and β cell function. We found that mirabegron treatment caused
an increase in type I fibers in skeletal muscle and had numerous
positive effects on skeletal muscle gene expression that likely
arose from increased PGC1α expression. These changes in muscle would be predicted to increase insulin sensitivity and fatty
acid oxidation. However, we were unable to detect ADRB3 mRNA
expression in muscle, and the β3-AR is also not expressed by β cells
(45). Thus, the effects on both β cells and muscle are probably indirect and caused by the numerous changes to SC WAT including
beiging, adipose tissue remodeling, and reduced inflammation.
Mirabegron did not induce BAT, and we found no evidence of
increased uncoupled respiration or lipid oxidation, even though
mirabegron treatment induced UCP1 protein expression in SC
WAT. Furthermore, the beneficial physiological effects of mira
begron treatment on glucose metabolism, insulin sensitivity, and
β cell function occurred paradoxically in the presence of increased
plasma NEFA levels. The increased NEFA levels did not result
in muscle lipotoxicity, which may be due to an increase in type
I fibers, suggesting that protective mechanisms are induced by
mirabegron treatment. This human study supports the previously proposed concept that adipose beiging has beneficial effects on
glucose metabolism, which can be UCP1 independent (21).

Discussion

Considerable evidence points to BAT and beige adipose tissue
as both a metabolic sink for glucose and lipids and a source of
“batokines” that affect peripheral tissues (20). β3-AR activation is
currently the best-known pharmacological approach for stimulating
brown and beige fat, and the β3-AR agonist mirabegron was demonstrated to be effective in activating BAT and inducing beige adipose
in humans (30–32). The current study differs from previous ones in
several important ways. In this study, we targeted an at-risk population: individuals with metabolic syndrome or prediabetes rather
than lean, healthy subjects. In addition, the standard FDA-approved
dose of mirabegron was used for 12 weeks and was very well tolerated, whereas previous studies used this β3 agonist only acutely and
sometimes in doses that had cardiovascular side effects. Finally,
this study focused on both SC WAT beiging as well as BAT, along
with a mechanistic examination of adipose and muscle.
The main findings of this study are that mirabegron treatment improved glucose metabolism in the absence of weight
loss and that this improvement in glucose metabolism was clinically significant. Indeed, a recent study suggests that in a population of nondiabetic subjects, changes in glucose tolerance
or HbA1c, as observed in our study, would be expected with a
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Figure 6. Mirabegron treatment increases alternatively activated macrophages in SC WAT. To characterize macrophage polarization, adipose tissue sections were
doubly stained for (A) CD86 and CD68 (M1) and (B) CD163 and CD68 (M2). (C) UCP1 was present in CD163+ cells in SC WAT. Yellow arrows point to UCP1+CD163+DAPI+
cells (scale bar: 50 μm). (D) UCP1+CD163+ cells were quantified in SC WAT before and after mirabegron treatment. Data indicate the mean ± SEM (n = 13). *P < 0.05
and ***P < 0.001, by paired, 2-tailed Student’s t test.

weight loss of more than 16% (46). Finally, our observations
that mirabegron treatment had beneficial effects (an increase
in both insulin sensitivity and β cell function) on cell types that
do not express the β3-AR indicate that SC WAT beiging affects
the function of peripheral tissues. Indeed, we identified a significant correlation between the change in SC WAT UCP1 expression and the change in the disposition index, but not with the
change in insulin sensitivity. Furthermore, we were not able to
identify plasma adipokines that changed in response to mirabegron treatment. This finding suggests that mirabegron treatment may have had only a modest effect on adipose tissue or
caused other tissues that express the β3-AR to influence peripheral tissues involved in glucose homeostasis. Indeed, a recent
study involving lean humans demonstrated that mirabegron
influences bile acid metabolism (32).
The effects of mirabegron on metabolism have recently been
studied in mice, and there are notable differences between those
studies (5, 47) and this one in humans. For instance, treatment
of ApoE–/– mice with mirabegron increased total and LDL cholesterol and promoted atherosclerosis (47), but the current study in
humans found a trend toward decreased cholesterol and no evidence for an increase in LDL. In another study in mice, mirabegron improved insulin sensitivity and glucose tolerance but also
induced weight loss and significantly increased BAT activity (5).
In this human study, mirabegron treatment clearly affected the
function of peripheral tissues involved in glucose homeostasis, but
there was no weight loss, and BAT activation was not a factor; the
presence of BAT in mice, but not obese humans, likely accounts
for the different responses. Other studies have demonstrated that
both cold and mirabegron are capable of inducing BAT recruitment
in humans (31, 32, 48–51). However, the participants in those studies were usually lean and younger than the subjects in this study,
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and some were preselected as having demonstrable BAT. Older,
obese humans often have little or no demonstrable BAT (16, 52).
One study did demonstrate detectable BAT in obese men but used
a prolonged cold exposure protocol (53). In this study, the inability
of mirabegron treatment to recruit BAT is probably because of the
low levels of BAT at baseline in this older, obese cohort.
Although adults with obesity have little BAT, there is considerable WAT, and both cold and mirabegron stimulate SC WAT beiging, with increases in UCP1, CIDEA, and TMEM26 (30). In spite
of a clear mirabegron-induced increase in UCP1 protein expression in SC WAT, we did not detect an increase in uncoupled respiration in purified mitochondria from WAT. In a previous study
using the same methods, cold exposure of lean subjects increased
uncoupled respiration in mitochondria isolated from SC WAT with
a similar level of induction of UCP1 (30). The reasons for the failure of mirabegron to induce uncoupling activity are unclear, but it
could be that mirabegron induced CIDEA, an inhibitor of UCP1
activity (54). Mirabegron may have affected ROS levels, which are
necessary to activate UCP1 (55).
Although there was no increase in uncoupled respiration with
mirabegron, the increase in lipolysis observed in this study and the
previously reported increase in HSL phosphorylation on a serine
residue that is a protein kinase A site (serine 660) (30) suggest that
mirabegron stimulated cAMP signaling in SC WAT. Furthermore,
mirabegron treatment caused numerous changes in the expression of genes, most of which are predicted to reduce adipose tissue
dysfunction. To gain a mechanistic understanding of the improvement in glucose metabolism, we attempted to identify changes in
plasma levels of adipokines and in proteins whose adipose gene
expression was altered by mirabegron. For instance, FGF21 has
many favorable metabolic effects and was upregulated in SC WAT
after mirabegron treatment (56). Resistin was initially discovered
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Figure 7. Mirabegron treatment reduces state 4 respiration but does not increase uncoupled respiration in purified mitochondria isolated from SC
WAT. Mitochondria were purified and the bioenergetics analyzed using an Oxytherm before and after mirabegron treatment as described in Methods. This
involved the sequential addition of adenosine diphosphate (ADP), oligomycin (Oligo), FFA (60 μM linoleic acid), fatty acid–free BSA, and trifluoromethoxy
carbonylcyanide phenylhydrazone (FCCP) (10 μm). (A and B) OCRs before and after treatment are shown. (C) The difference between oligomycin and BSA
was calculated before and after treatment. Data indicate the mean ± SEM (n = 12). *P = 0.05, by Wilcoxon matched-pairs, signed-rank test.

to be a factor secreted by adipocytes that causes insulin resistance in mice (57). Studies of resistin in humans initially yielded
conflicting results; however, 2 large studies identified resistin as a
risk factor for the development of diabetes (58, 59). We were not
able to identify changes in the plasma levels of FGF21, resistin,
adiponectin, leptin, or adipsin. Overall, our findings suggest that
mirabegron treatment affected many different pathways that have
an impact on adipose tissue function, and it will be important to
identify mechanisms linking changes in SC WAT to improved glucose homeostasis in future studies.
One of the most interesting findings from this study was the
change in skeletal muscle fiber types. The switch in muscle fiber
type induced by mirabegron treatment is rather remarkable, since
muscle fiber type is relatively resistant to a transition from type II
to type I, even with significant interventions such as exercise and
weight loss (60, 61). The β2-AR is expressed in muscle, and administration of β2-AR agonists causes hypertrophy as well as a shift
from type I to type II fibers (62, 63). We did not detect an increase
in fiber size or type I to type II switching, indicating that mirabegron did not activate β2-ARs, consistent with the lack of cardiovascular side effects. Mirabegron increased PGC1A mRNA levels
as well as the expression of genes regulated by PGC1α. PGC1α
promotes type I fiber induction in mice (38), and the increase in
PGC1A after mirabegron treatment is thus likely important for a
number of changes including observations that lipotoxicity was
not increased despite increased plasma NEFAs and that insulin
sensitivity was increased. It will therefore be important to identify the mechanism for PGC1A induction by mirabegron treatment
and to consider that beige adipose may be the source of the factor.
β Cell function was increased by mirabegron treatment. A
recent study in mice demonstrated an acute effect of β3-AR agonism on insulin secretion, and this effect was entirely dependent
on adipose tissue lipolysis, since it was completely blocked in mice
with adipose tissue triglyceride lipase (ATGL) deficiency (45). This
observation suggests that the β3-AR is not expressed on pancreatic
β cells in rodents and illustrates a communication between adipose tissue and β cells. In addition to NEFAs, adiponectin, leptin,
and adipsin are proteins secreted from adipose tissue that have an
impact on β cells (64–66). The results of our study indicate that the
change in the disposition index, a measure of β cell function, correlated with both the change in SC WAT UCP1 expression and the

change in plasma NEFA levels, suggesting a relationship between
the effect of mirabegron on SC WAT and β cell function. It is possible that this effect is mediated directly by increased NEFAs. It
will be important to determine whether this effect persists under
longer-term mirabegron treatment. Although NEFAs stimulate β
cell insulin secretion acutely, the compensatory mechanisms of β
cells during chronic exposure to increased NEFAs are detrimental
to insulin secretion (41–43). Another possibility is that stimulation
of beige adipose results in the release of additional factors that
protect β cell function.
A leading hypothesis for the development of adipose dysfunction in obesity is adipocyte expansion against a rigid ECM, leading
to adipocyte necrosis and macrophage recruitment (24, 25, 67).
Mirabegron treatment resulted in reduced mRNA expression of
collagen VI and several genes involved in adipose tissue remodeling. Although mirabegron treatment induced lipolysis, we did not
observe any change in adipocyte size (data not shown). This suggests that the changes in ECM gene expression may be due to the
induction of beiging, which is linked to reduced fibrosis and a less
rigid ECM (11, 23). In addition to the changes in ECM genes, the
number of alternatively activated macrophages (CD163+CD68+)
increased in SC WAT after mirabegron treatment, suggesting an
environment that is less inflammatory and more reparative. Macrophages have been reported to be recruited into adipose tissue in
response to increased lipolysis to buffer FFAs (68). We observed
that the CD163+CD68+ macrophages recruited into SC WAT
expressed UCP1. Although uncoupling activity in the adipose tissue did not increase overall, it is possible that UCP1 was active in
these macrophages as a mechanism of oxidizing lipids. UCP1 was
also expressed in CD206+ macrophages, which increased after
mirabegron treatment but did not reach statistical significance
(data not shown; P = 0.12). The identification of UCP1 in adipose
tissue macrophages (Figure 6C) partly explains the punctate
nature of UCP1 staining that we observed in human WAT.
Limitations of the study. This study was designed to be a proof
of concept, since, to our knowledge, β3-AR agonists have not been
studied in obese humans, and we sought to comprehensively
characterize the response to mirabegron using both basic science
and clinical techniques. Furthermore, this study was not placebo
controlled, and the majority of the subjects were female. A randomized, blinded, placebo-controlled study with a larger number
jci.org   Volume 130   Number 5   May 2020
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of participants and males will be necessary to determine whether
there are sex differences and to identify small changes that may
have been missed in this study. For instance, our data indicate that
mirabegron at the FDA-approved dose of 50 mg/day is specific
for β3-ARs, which is based on a lack of cardiovascular side effects.
With the sample size of this study, we cannot completely rule out
β2-AR agonism, which could, for instance, affect β cell function
directly or indirectly via other cells in the islet. A placebo control
group will also be necessary to rule out a placebo effect for some
of the small changes identified in this study, such as the small but
consistent increase in GIR. Despite these limitations, we believe
this study forms a strong basis for future studies on mirabegron,
as described below.
Conclusions, perspectives, and future goals. β3-AR agonists were
initially developed as antiobesity agents. Although β3-AR agonists
induce weight loss in rodents, we did not observe weight loss in
the subjects in this study. This could be due to the relatively low
levels of BAT in humans, the mirabegron dose used, or the fact
that humans will compensate for increased energy expenditure
with increased food intake. Alternatively, it is possible that the
50-mg/day dose was too low to induce beiging and UCP1 activation to a level that would increase energy expenditure and weight
loss. However, even without weight loss or BAT activation, this
relatively low dose was sufficient to improve insulin sensitivity
and β cell function, despite the fact that NEFA levels increased.
Higher doses of mirabegron would likely induce stronger beiging
and increased lipid oxidation, which may reduce NEFAs; however, unwanted cardiovascular side effects may be limiting (31, 32).
It will be important to determine whether long-term mirabegron
treatment at the dose used in this study would maintain improved
β cell function and delay the onset of diabetes in prediabetic subjects. Finally, it would be important to know whether mirabegron
improves glucose homeostasis in individuals with type 2 diabetes.

Methods

Study design and human subjects. This study was intended to examine
the metabolic effects of mirabegron in obese, insulin-resistant humans
at the dose approved by the FDA for overactive bladder. Hence, we
recruited 13 sedentary subjects, aged 35 to 65 years, who had a BMI
over 27 and either prediabetes, on the basis of HbA1c and a standard 75
g OGTT, or normal glucose tolerance (NGT) but more than 3 features
of metabolic syndrome (MetS). Nine of the 13 subjects met at least 1
criterion for prediabetes at baseline: impaired fasting glucose (100–125
mg/dL), impaired glucose tolerance (120-minute glucose: 140–199
mg/dL), or HbA1c of 5.7% to 6.4%. In addition to the OGTT, baseline
studies were performed in fasted subjects early in the morning in a
quite, temperature-controlled room (22°C) and included measurement
of body composition by dual-energy x-ray absorptiometry (DEXA)
scan and resting metabolic rate (RMR) with a metabolic cart. Other
baseline studies included a euglycemic clamp, SC WAT and muscle
(vastus lateralis) biopsies, and PET-CT scans under cold stimulation to
quantify BAT.
The subjects were recruited from the Lexington, Kentucky, area
throughout the year, and all subjects had normal thyroid function, no
chronic inflammatory conditions, and were not taking any medications, such as beta blockers, steroids, or insulin sensitizers, that would
interfere with the study. The subjects were asked to continue their
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usual diet and level of activity. After completing the baseline studies
(OGTT, euglycemic clamp, fat and muscle biopsies, and PET-CT), the
participants were treated with mirabegron (50 mg/day) for 12 weeks,
after which the initial studies were repeated. The Clinicaltrials.gov
identifier is NCT02919176.
Biopsies. An incisional biopsy of adipose tissue from the abdomen
was obtained as described previously (69). Briefly, approximately 4
grams of tissue was removed from the abdomen, most of which was
used for the preparation of mitochondria for mitochondrial bioenergetics analysis (30). The remainder was either frozen at –80°C or used
for immunohistochemical analyses. A muscle biopsy from the vastus
lateralis was also obtained using a Bergstrom needle as described previously (70). Briefly, approximately 100 mg of each biopsy was mounted with fibers perpendicular to a cork using tragacanth gum; this was
snap-frozen in liquid nitrogen–cooled isopentane and then stored at
–80°C until sectioning.
Euglycemic clamp. Peripheral insulin sensitivity was measured
using a euglycemic clamp, as described previously (71). The subjects
arrived in the fasted state, IVs were inserted, and euglycemia was
maintained through the variable infusion of 20% glucose and frequent
blood glucose measurement during an insulin infusion of 1.0 mU/kg/
min. A steady state was generally attained at 2 hours, and the glucose
infusion rate was determined during the final 30 minutes.
Assessment of BAT. Cold-stimulated PET-CT for the measurement
of BAT was performed as described previously (31, 72). After an overnight fast, the subjects were brought to the PET-CT suite 120 minutes
before the scan and outfitted with a cooling vest that circulated water
at 14°C. Sixty minutes before the scan, 440 MBq 18F-FDG was injected
intravenously. Images were acquired using a Discovery LS Multidetector Helical PET-CT Scanner (GE Medical Systems). PET data were
acquired from the eyes to the thighs, and both PET and CT images
were reconstructed as axial sections at 4.25-mm spacing and then
reformatted by the viewer software. BAT mass and activity were quantified using the PET-CT Viewer shareware, and BAT in each axial slice
was classified on a pixel-by-pixel basis when CT was in the range of
–250 to –10 Hounsfield units and when the maximal standard uptake
value (SUVmax) was 2.0 or higher in the cervical, supraclavicular, and
anterior thoracic depots from C3 to T7. Areas of 18F-FDG uptake on
PET colocalizing with regions of fat identified on CT were quantified
by their average SUV (SUVavg), and detectable BAT volume was calculated as the sum of pixels meeting this classification criteria multiplied by the pixel volume (64.8 mm3).
IHC on adipose tissue and muscle. IHC and quantification of
UCP1, TMEM26, and CIDEA expression in SC WAT were performed
as described previously (30). We performed immunohistochemical analyses of macrophages (CD163+CD68+, CD206+CD68+, or
CD86+CD68+) on 5-μm formalin-fixed, paraffin-embedded SC WAT
sections. Tissue was deparaffinized and blocked with hydrogen peroxide, rinsed, and then blocked first with a Streptavidin/Biotin Blocking Kit (SP-2002, Vector Laboratories) followed by 2.5% horse serum.
M1 macrophages were identified by costaining with rabbit anti-CD86
(ab53004, Abcam) and mouse anti-CD68 (ab955, Abcam) antibodies; M2 macrophages were identified by costaining with rabbit antiCD163 (ab182422, Abcam) and anti-CD68 antibodies. The primary
antibodies were incubated individually overnight in 1% horse serum.
The number of CD163 macrophages that costained with UCP1 was
determined using mouse anti-CD163 (HM2157, Hycult Biotech) and
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rabbit anti-UCP1 (custom antibody J2648, ECM Biosciences). Amplification was performed with either goat anti–mouse IgG biotin (115065-205, Jackson ImmunoResearch) or donkey anti–rabbit IgG biotin
(711-065-152, Jackson ImmunoResearch) and then streptavidin-HRP
(S911, Thermo Fisher Scientific), followed by washing and incubation
with Alexa Fluor Tyramide Reagent (Thermo Fisher Scientific). Sections were mounted and nuclei stained using VECTASHIELD Antifade Mounting Media with DAPI (H-1800, Vector Laboratories). Macrophages were counted when cells were triple-stained with DAPI and
CD68, CD86, or CD163. UCP1+CD163+ cells were triple-stained with
CD163, UCP1, and DAPI. Macrophages were counted within fields of
adipocytes and not in connective tissue. All data were normalized to
adipocyte numbers. Images were captured with an upright Zeiss fluorescence microscope.
We performed immunohistochemical analyses on muscle biopsies obtained from the vastus lateralis as described previously (73).
Briefly, frozen muscle sections were cut at 8 μm, air-dried, and stored
at –20°C. Sections were incubated overnight with isotype-specific
anti-mouse antibodies against MyHC I IgG2B (BA.D5), MyHC IIa
IgG1 (SC.71), and MyHC IIx (6H1), obtained from the Developmental Studies Hybridoma Bank. Sections were then incubated with the
following secondary antibodies: goat anti–mouse IgG2b Alexa Fluor
647, anti–mouse IgG1 Alexa Fluor 488, and anti–mouse IgM Alexa Fluor 555 (Invitrogen, Thermo Fisher Scientific). The sections were then
mounted using VECTASHIELD Anti-fade Mounting Media and postfixed in methanol. Five to 7 images were captured at ×20 magnification using an AxioImager M1 upright fluorescence microscope (Zeiss).
Fiber type distribution was quantified manually in a blinded manner.
mRNA quantification. Muscle and adipose mRNA was isolated
using TRIzol extraction and purification with RNeasy Lipid Tissue
Mini Kits (QIAGEN). The quantity and quality were RNA determined
using an Agilent 2100 Bioanalyzer. Multiplex analysis of SC WAT
gene expression was performed using the NanoString nCounter system (Nanostring) and a custom code set. The data were normalized to
the geometric mean of 6 housekeeping genes; the genes and accession
numbers of the NanoString custom code set are provided in Supplemental Table 5. Muscle gene expression was analyzed by real-time
RT-PCR as described previously (69), and the data were normalized
to the geometric mean of 6 housekeeping genes (ACTB, PPIA, PPIB,
TBP, TUBB, and UBC9). The primer sequences are shown in Supplemental Table 6.
Quantification of lipids in muscle biopsies. Approximately 10 milligrams of the vastus lateralis biopsy was weighed and then extracted
with acidified organic solvents. DAGs and ceramides were quantified
as described perviously (74). TGs were quantified in the extract using
colorimetric TG assays (T7532, Point Scientific). Briefly, lipid extract
(10 μL) was dried for 5 minutes, and 10 μL 0.1% SDS in 0.9% NaCl
was added and then incubated for 10 minutes at 37°C. Prewarmed TG
reagent (1 mL) was added, and the reaction was incubated at 37°C for
5 minutes. The absorbance (A500) was measured with a Bio-Rad spectrophotometer within 30 minutes. Lipid levels were normalized to the
tissue weight.
Myotube treatment with adipocyte CM. Adult-derived human adipocyte stem cells (ADHASCs) were cultured and differentiated as
described previously (75). In brief, preadipocytes were incubated for
48 hours after reaching confluence and induced to differentiate into
adipocytes with adipocyte differentiation medium (50% DMEM:

50% Ham’s F-10); 3% FBS (Invitrogen, Thermo Fisher Scientific);
15 mM HEPES, pH 7.4, 33 μM biotin (MilliporeSigma); 17 μM pantothenate (MilliporeSigma); 1 μM dexamethasone (MilliporeSigma);
0.25 mM 3-isobutyl-1-methylxanthine (IBMX) (MilliporeSigma); 1 ×
10 –7 M insulin (Novo Nordisk); and 1 μM rosiglitazone (SmithKline
Beecham) for 3 days. The cells were then incubated with adipocyte differentiation medium without IBMX and rosiglitazone, with
medium changes every 3 days until 80%–90% of the cells had lipid droplets (7–10 days). Adipocyte CM was prepared by incubating
differentiated ADHASCs with DMEM with 2% FBS for 24 hours and
then with DMEM with 2%FBS and 0.1% DMSO (vehicle control) or
100 nM mirabegron (Cayman Chemical) for 16 hours. CM was also
isolated and mirabegron added to this medium (100 nM). Adipocyte
CM was filtered with a 0.2-μm filter and frozen at –80°C for later
use. Primary myoblasts from human skeletal muscle biopsies from
healthy subjects were provided by Charlotte Peterson (University of
Kentucky, Lexington, Kentucky, USA). The myoblasts were differentiated in DMEM with 2% FBS for 10 days. Fully differentiated myotubes were treated with 25 nM mirabegron or 25% adipocyte CM for
16 hours, and total RNA was prepared for mRNA expression analysis
using real-time RT-PCR.
NEFA and glycerol measurements in plasma and adipose explant
secretions. Adipose explant secretions were prepared by incubating 0.5
grams of the SC WAT biopsy in 2 mL Ringer’s solution supplemented
with 1% lipid-free BSA at 37°C for 1 hour. Glycerol in the explant secretion was then measured with a High-Sensitivity Free Glycerol Fluorometric Assay Kit (MAK270, MilliporeSigma). Glycerol in plasma
was measured with Free Glycerol Reagent (F6428, MilliporeSigma).
NEFAs in plasma or adipose explant secretions were measured with
HR Series NEFA-HR(2) Color Reagents (999-34691, 995-34791, 99134891, 993-35191, FUJIFILM Wako Diagnostics)
Mitochondrial bioenergetics. Bioenergetics of mitochondria purified from the SC WAT biopsies were determined using an Oxytherm
System (Hansatech) as previously described (30).
Statistics. A paired Student’s t test or Wilcoxon matched-pairs,
signed-rank test was performed to compare the results before and
after mirabegron treatment. Oral glucose tolerance was assessed by
a repeated-measures 2-way ANOVA with Sidak’s multiple comparisons test. Spearman’s correlations were used to assess associations
between beiging, plasma NEFA levels, and β cell function. Multiple
comparisons were analyzed by 1-way ANOVA and Tukey’s multiple
comparisons test. Data were analyzed using GraphPad Prism, version
8.0 (GraphPad Software). All tests were 2 sided, and statistical significance was set at a P value of 0.05 or less.
Study approval. All subjects provided informed consent, and the
protocols were approved by the IRB of the University of Kentucky.

Author contributions

PAK, EEDV, PGS, AJM, and BSF designed the experiments, analyzed data, and wrote the manuscript. BZ, HM, ALC, ZRJ, JC, and
HJV performed experiments. PMW analyzed data. RHEK performed cold-stimulated PET CT studies and analyzed data.

Acknowledgments

We wish to thank the staff of the University of Kentucky Clinical
Research Unit for assistance with this study and Dorothy Ross for
coordinating the recruitment of the participants. We acknowljci.org   Volume 130   Number 5   May 2020

2329

CLINICAL MEDICINE

The Journal of Clinical Investigation  

edge Charlotte Peterson for providing the primary myoblasts and
Rachel Davidowitz for her help with the graphical abstract. This
study was funded by NIH grants DK112282, P30GM127211, and
DK 71349 and by CTSA, NIH grant UL1TR001998.
1. Arch JR. Challenges in β(3)-adrenoceptor agonist
drug development. Ther Adv Endocrinol Metab.
2011;2(2):59–64.
2. Arch JR. beta(3)-Adrenoceptor agonists: potential, pitfalls and progress. Eur J Pharmacol.
2002;440(2-3):99–107.
3. Arch JR, et al. Treatment of obesity with thermogenic beta-adrenoceptor agonists: studies on BRL
26830A in rodents. Int J Obes. 1984;8 Suppl 1:1–11.
4. Arch JR, Ainsworth AT. Thermogenic and antiobesity activity of a novel beta-adrenoceptor
agonist (BRL 26830A) in mice and rats. Am J Clin
Nutr. 1983;38(4):549–558.
5. Hao L, et al. Beneficial metabolic effects of
mirabegron in vitro and in high-fat diet-induced obese mice. J Pharmacol Exp Ther.
2019;369(3):419–427.
6. Frontini A, Cinti S. Distribution and development
of brown adipocytes in the murine and human
adipose organ. Cell Metab. 2010;11(4):253–256.
7. Wu J, et al. Beige adipocytes are a distinct type of
thermogenic fat cell in mouse and human. Cell.
2012;150(2):366–376.
8. Seale P, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue
in mice. J Clin Invest. 2011;121(1):96–105.
9. Cohen P, et al. Ablation of PRDM16 and beige
adipose causes metabolic dysfunction and
a subcutaneous to visceral fat switch. Cell.
2014;156(1-2):304–316.
10. Min SY, et al. Human ‘brite/beige’ adipocytes
develop from capillary networks, and their
implantation improves metabolic homeostasis in
mice. Nat Med. 2016;22(3):312–318.
11. Hasegawa Y, et al. Repression of adipose tissue
fibrosis through a PRDM16-GTF2IRD1 complex
improves systemic glucose homeostasis. Cell
Metab. 2018;27(1):180–194.e6.
12. Chen Y, et al. Thermal stress induces glycolytic
beige fat formation via a myogenic state. Nature.
2019;565(7738):180–185.
13. Cannon B, Nedergaard J. Brown adipose tissue:
function and physiological significance. Physiol
Rev. 2004;84(1):277–359.
14. van Marken Lichtenbelt WD, et al. Cold-activated
brown adipose tissue in healthy men. N Engl J
Med. 2009;360(15):1500–1508.
15. Virtanen KA, et al. Functional brown adipose tissue in healthy adults. N Engl J Med.
2009;360(15):1518–1525.
16. Saito M, et al. High incidence of metabolically
active brown adipose tissue in healthy adult
humans: effects of cold exposure and adiposity.
Diabetes. 2009;58(7):1526–1531.
17. Cypess AM, et al. Identification and importance
of brown adipose tissue in adult humans. N Engl J
Med. 2009;360(15):1509–1517.
18. Klepac K, Georgiadi A, Tschöp M, Herzig S. The
role of brown and beige adipose tissue in glycaemic control. Mol Aspects Med. 2019;68:90–100.
19. Porter C, Chondronikola M, Sidossis LS. The

2330

Address correspondence to: Philip A. Kern, Division of Endocrinology, CTW 521, University of Kentucky, 900 South Limestone
Street, Lexington, Kentucky 40536, USA. Phone: 859.218.1394;
philipkern@uky.edu.

therapeutic potential of brown adipocytes
in humans. Front Endocrinol (Lausanne).
2015;6:156.
20. Kajimura S, Spiegelman BM, Seale P. Brown and
beige fat: physiological roles beyond Heat Generation. Cell Metab. 2015;22(4):546–559.
21. Ikeda K, et al. UCP1-independent signaling involving SERCA2b-mediated calcium cycling regulates
beige fat thermogenesis and systemic glucose
homeostasis. Nat Med. 2017;23(12):1454–1465.
22. Kazak L, et al. A creatine-driven substrate cycle
enhances energy expenditure and thermogenesis
in beige fat. Cell. 2015;163(3):643–655.
23. Wang W, et al. A PRDM16-driven metabolic signal from adipocytes regulates precursor cell fate.
Cell Metab. 2019;30(1):174–189.e5.
24. Crewe C, An YA, Scherer PE. The ominous triad
of adipose tissue dysfunction: inflammation,
fibrosis, and impaired angiogenesis. J Clin Invest.
2017;127(1):74–82.
25. Sun K, Kusminski CM, Scherer PE. Adipose
tissue remodeling and obesity. J Clin Invest.
2011;121(6):2094–2101.
26. Sidossis LS, et al. Browning of subcutaneous white
adipose tissue in humans after severe adrenergic
stress. Cell Metab. 2015;22(2):219–227.
27. Petruzzelli M, et al. A switch from white to brown
fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014;20(3):433–447.
28. Frontini A, et al. White-to-brown transdifferentiation of omental adipocytes in patients affected
by pheochromocytoma. Biochim Biophys Acta.
2013;1831(5):950–959.
29. Kir S, et al. Tumour-derived PTH-related protein
triggers adipose tissue browning and cancer
cachexia. Nature. 2014;513(7516):100–104.
30. Finlin BS, et al. Human adipose beiging in
response to cold and mirabegron. JCI Insight.
2018;3(15):121510.
31. Cypess AM, et al. Activation of human brown adipose tissue by a β3-adrenergic receptor agonist.
Cell Metab. 2015;21(1):33–38.
32. Baskin AS, et al. Regulation of human adipose
tissue activation, gallbladder size, and bile acid
metabolism by a β3-adrenergic receptor agonist.
Diabetes. 2018;67(10):2113–2125.
33. Loh RKC, Formosa MF, La Gerche A, Reutens AT,
Kingwell BA, Carey AL. Acute metabolic and cardiovascular effects of mirabegron in healthy individuals. Diabetes Obes Metab. 2019;21(2):276–284.
34. Nitti VW, et al. Safety and tolerability of the
β3-adrenoceptor agonist mirabegron, for the
treatment of overactive bladder: results of a
prospective pooled analysis of three 12-week
randomised phase III trials and of a 1-year
randomised phase III trial. Int J Clin Pract.
2014;68(8):972–985.
35. Pisprasert V, Ingram KH, Lopez-Davila MF,
Munoz AJ, Garvey WT. Limitations in the use of
indices using glucose and insulin levels to predict
insulin sensitivity: impact of race and gender

jci.org   Volume 130   Number 5   May 2020

and superiority of the indices derived from oral
glucose tolerance test in African Americans. Diabetes Care. 2013;36(4):845–853.
36. Bergman RN, Finegood DT, Kahn SE. The
evolution of beta-cell dysfunction and insulin
resistance in type 2 diabetes. Eur J Clin Invest.
2002;32 Suppl 3:35–45.
37. Fan W, Atkins AR, Yu RT, Downes M, Evans RM.
Road to exercise mimetics: targeting nuclear
receptors in skeletal muscle. J Mol Endocrinol.
2013;51(3):T87–T100.
38. Lin J, et al. Transcriptional co-activator PGC-1
alpha drives the formation of slow-twitch muscle
fibres. Nature. 2002;418(6899):797–801.
39. Mason RR, Watt MJ. Unraveling the roles of
PLIN5: linking cell biology to physiology. Trends
Endocrinol Metab. 2015;26(3):144–152.
40. Hinkle RT, Hodge KM, Cody DB, Sheldon RJ,
Kobilka BK, Isfort RJ. Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are
mediated by the beta2-adrenergic receptor. Muscle Nerve. 2002;25(5):729–734.
41. Nolan CJ, Madiraju MS, Delghingaro-Augusto V,
Peyot ML, Prentki M. Fatty acid signaling in the
beta-cell and insulin secretion. Diabetes. 2006;55
Suppl 2:S16–S23.
42. Prentki M, Matschinsky FM, Madiraju SR. Metabolic signaling in fuel-induced insulin secretion.
Cell Metab. 2013;18(2):162–185.
43. Ježek P, Jabůrek M, Holendová B, Plecitá-Hlavatá
L. Fatty acid-stimulated insulin secretion vs. lipotoxicity. Molecules. 2018;23(6):E1483.
44. Distel RJ, Robinson GS, Spiegelman BM. Fatty
acid regulation of gene expression. Transcriptional and post-transcriptional mechanisms.
J Biol Chem. 1992;267(9):5937–5941.
45. Heine M, et al. Lipolysis triggers a systemic
insulin response essential for efficient energy
replenishment of activated brown adipose tissue
in mice. Cell Metab. 2018;28(4):644–655.e4.
46. Magkos F, et al. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with
obesity. Cell Metab. 2016;23(4):591–601.
47. Sui W, et al. Bladder drug mirabegron exacerbates atherosclerosis through activation of brown
fat-mediated lipolysis. Proc Natl Acad Sci USA.
2019;116(22):10937–10942.
48. Hanssen MJ, et al. Short-term cold acclimation improves insulin sensitivity in patients
with type 2 diabetes mellitus. Nat Med.
2015;21(8):863–865.
49. van der Lans AA, et al. Cold acclimation recruits
human brown fat and increases nonshivering thermogenesis. J Clin Invest. 2013;123(8):3395–3403.
50. Yoneshiro T, et al. Recruited brown adipose tissue
as an antiobesity agent in humans. J Clin Invest.
2013;123(8):3404–3408.
51. Hanssen MJ, et al. Short-term cold acclimation
recruits brown adipose tissue in obese humans.
Diabetes. 2016;65(5):1179–1189.

CLINICAL MEDICINE

The Journal of Clinical Investigation  
52. Vijgen GH, Bouvy ND, Teule GJ, Brans B, Schrauwen P, van Marken Lichtenbelt WD. Brown
adipose tissue in morbidly obese subjects. PLoS
ONE. 2011;6(2):e17247.
53. Chondronikola M, et al. Brown adipose tissue
activation is linked to distinct systemic effects
on lipid metabolism in humans. Cell Metab.
2016;23(6):1200–1206.
54. Fischer AW, et al. UCP1 inhibition in Cidea-overexpressing mice is physiologically counteracted
by brown adipose tissue hyperrecruitment. Am J
Physiol Endocrinol Metab. 2017;312(1):E72–E87.
55. Chouchani ET, et al. Mitochondrial ROS regulate
thermogenic energy expenditure and sulfenylation of UCP1. Nature. 2016;532(7597):112–116.
56. Fisher FM, Maratos-Flier E. Understanding
the physiology of FGF21. Annu Rev Physiol.
2016;78:223–241.
57. Schwartz DR, Lazar MA. Human resistin: found
in translation from mouse to man. Trends Endocrinol Metab. 2011;22(7):259–265.
58. Chen BH, et al. Circulating levels of resistin and
risk of type 2 diabetes in men and women: results
from two prospective cohorts. Diabetes Care.
2009;32(2):329–334.
59. Heidemann C, et al. Total and high-molecular-weight adiponectin and resistin in relation to
the risk for type 2 diabetes in women. Ann Intern
Med. 2008;149(5):307–316.

60. Kern PA, Simsolo RB, Fournier M. Effect of
weight loss on muscle fiber type, fiber size,
capillarity, and succinate dehydrogenase
activity in humans. J Clin Endocrinol Metab.
1999;84(11):4185–4190.
61. Wilson JM, Loenneke JP, Jo E, Wilson GJ, Zourdos
MC, Kim JS. The effects of endurance, strength,
and power training on muscle fiber type shifting.
J Strength Cond Res. 2012;26(6):1724–1729.
62. Ryall JG, Lynch GS. The potential and the pitfalls
of beta-adrenoceptor agonists for the management of skeletal muscle wasting. Pharmacol Ther.
2008;120(3):219–232.
63. Ohnuki Y, et al. Role of masseter muscle β2-adrenergic signaling in regulation of muscle activity, myosin heavy chain transition, and hypertrophy. J Pharmacol Sci. 2013;123(1):36–46.
64. Lo JC, et al. Adipsin is an adipokine that improves
β cell function in diabetes. Cell. 2014;158(1):41–53.
65. Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of
metabolic homeostasis through adipose tissue
crosstalk. Cell Metab. 2016;23(5):770–784.
66. Holland WL, et al. Receptor-mediated activation of
ceramidase activity initiates the pleiotropic actions
of adiponectin. Nat Med. 2011;17(1):55–63.
67. Sun K, Tordjman J, Clément K, Scherer PE. Fibrosis and adipose tissue dysfunction. Cell Metab.
2013;18(4):470–477.

68. Kosteli A, et al. Weight loss and lipolysis promote
a dynamic immune response in murine adipose
tissue. J Clin Invest. 2010;120(10):3466–3479.
69. Finlin BS, et al. Mast cells promote seasonal
white adipose beiging in humans. Diabetes.
2017;66(5):1237–1246.
70. Walton RG, et al. Human skeletal muscle macrophages increase following cycle training and are
associated with adaptations that may facilitate
growth. Sci Rep. 2019;9(1):969.
71. Finlin BS, et al. Effect of rifaximin treatment on
endotoxemia and insulin sensitivity in humans.
J Endocr Soc. 2019;3(9):1641–1651.
72. Chen KY, et al. Brown adipose reporting criteria
in imaging studies (BARCIST 1.0): recommendations for standardized FDG-PET/CT experiments
in humans. Cell Metab. 2016;24(2):210–222.
73. Murach KA, et al. Depletion of Pax7+ satellite
cells does not affect diaphragm adaptations
to running in young or aged mice. J Physiol.
2017;595(19):6299–6311.
74. Walton RG, et al. Increasing adipocyte lipoprotein lipase improves glucose metabolism
in high fat diet-induced obesity. J Biol Chem.
2015;290(18):11547–11556.
75. Rasouli N, et al. Association of scavenger receptors in adipose tissue with insulin resistance in
nondiabetic humans. Arterioscler Thromb Vasc
Biol. 2009;29(9):1328–1335.

jci.org   Volume 130   Number 5   May 2020

2331

